Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06960798 · ClinicalTrials.gov registry record
Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
A clinical trial of Prostate Cancer, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT06960798: Recruiting study of Prostate Cancer, sponsored by University of Oklahoma.
NCT06960798 is a study of Prostate Cancer that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 150 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06960798, a study of Prostate Cancer, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to analyze tumor tissue samples from patients of Native American identity with prostate cancer. By examining these samples, researchers hope to understand how different genes in your tumor can influence treatment decisions, how your cancer progresses and the outcome of your cancer.
Primary Outcome
Comprehensively characterize the genomic profile of prostate cancer in Native American patients compared to Caucasian patients. Genetic testing will be conducted using Caris Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS).
Conditions Studied
Interventions
- OTHER Blood Draw
- OTHER Bio-specimen Collection
Study Locations (1)
Oklahoma
- OU Health Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-05-02 |
| Est. Completion | 2029-06-30 |
What NCT06960798 shows while recruiting
NCT06960798 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Blood Draw is the first listed.
NCT06960798 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06960798 about?
NCT06960798 is a clinical study titled "Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)". The purpose of this study is to analyze tumor tissue samples from patients of Native American identity with prostate cancer. By examining these samples, researchers hope to understand how different genes in your tumor can influence treatment decisions, how your cancer progresses and the outcome of y...
What is the current status of trial NCT06960798?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2026-05-02. Estimated completion is 2029-06-30.
What conditions does trial NCT06960798 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06960798?
The interventions under investigation include: Blood Draw (OTHER), Bio-specimen Collection (OTHER).
Who is sponsoring clinical trial NCT06960798?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06960798 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06960798's enrollment target sits among peer trials
150 260th of 735 higher than 464 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02455479 · 150 participants · Phase 1
Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI